DFTX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWDefinium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Pipeline Highlights

Nov 9, 2026

8-K

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

Sep 14, 2026

8-K

Definium Therapeutics Receives FDA Breakthrough Therapy Designation for DT120 (lysergide) ODT in Major Depressive Disorder Following Positive Phase 3 Results

Sep 8, 2026

8-K

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

Aug 12, 2026

8-K

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Positive Phase 3 Emerge Study Results

Aug 6, 2026

8-K

Definium Therapeutics, Inc. Announces Proposed Public Offering

Jun 24, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Jun 24, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $500,000,000 | Bank: J.P. Morgan, Jefferies, Leerink Partners, BofA Securities, Evercore ISI, Stifel, Oppenheimer & Co., LifeSci Capital

Jun 22, 2026

424B5

REGISTERED OFFERING

Oct 30, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: Jefferies, Leerink Partners, Evercore ISI

Oct 29, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 5,497,506

Oct 22, 2024

424B7

SHARE RESALE REGISTRATION | Shares amount: 8,000,000

Oct 17, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 16, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 20, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

May 5, 2025

S-3ASR

SHELF | ATM | Offering amount: $150,000,000.00

Jun 28, 2024

S-8

Registration

Jun 28, 2024

S-3

SHARE RESALE REGISTRATION | Shares amount: 13,497,506 | Share price: $6.00 | Conversion price: $4.01 EFFECTIVE

Apr 2, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

FMR LLC (Filed by)

Nov 5, 2026

Karlin Daniel (Reporting)

Sep 29, 2026

Barrow Robert (Reporting)

Sep 29, 2026

Wiley Matthew T. (Reporting)

Sep 29, 2026

Sullivan Mark (Reporting)

Sep 29, 2026

Roberts Brandi (Reporting)

Sep 29, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 30, 2024

CORRESP

Form CORRESP - Correspondence

Apr 26, 2024

LETTER

Form UPLOAD - SEC-generated letter

Apr 9, 2024

CORRESP

Form CORRESP - Correspondence

Apr 28, 2023

LETTER

Form UPLOAD - SEC-generated letter

Apr 28, 2023

LETTER

Form UPLOAD - SEC-generated letter

Apr 27, 2023

Definium Therapeutics, Inc. DFTX · SEC Filings